Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trevogrumab - Regeneron Pharmaceuticals

Next Previous
Search
Drug Profile

Trevogrumab - Regeneron Pharmaceuticals

Alternative Names: GDF8; REGN-1033; SAR-391786

Latest Information Update: 21 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals; Sanofi
  • Class Monoclonal antibodies; Obesity therapies; Osteoporosis therapies
  • Mechanism of Action Myostatin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Obesity; Sarcopenia
  • Phase I Musculoskeletal disorders
  • No development reported Osteoporosis

Most Recent Events

  • 04 Feb 2025 Regeneron Pharmaceuticals completes the phase II COURAGE trial in Puerto Rico and USA (NCT06299098)
  • 21 Jun 2024 Trevogrumab is still in phase I trials for Musculoskeletal disorders in New Zealand
  • 21 Jun 2024 Efficacy and adverse events data from a phase I trial in Musculoskeletal disorders presented at the 84th Annual Scientific Sessions of the American Diabetes Association (ADA-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top